New drug may stop MS symptoms from returning between treatments
NCT ID NCT07389590
First seen Feb 05, 2026 · Last updated May 21, 2026 · Updated 13 times
Summary
This study looks at whether switching from ocrelizumab to ublituximab can reduce or delay the return of MS symptoms in 50 adults aged 18-65. Participants must have relapsing MS and have been on ocrelizumab for at least one year. The goal is to improve quality of life by easing fatigue, depression, and movement issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins University
RECRUITINGBaltimore, Maryland, 21287, United States
Conditions
Explore the condition pages connected to this study.